Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities
- 31 December 1995
- journal article
- case report
- Published by Elsevier in The American Journal of Medicine
- Vol. 99 (6) , 685-688
- https://doi.org/10.1016/s0002-9343(99)80259-9
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Population study of dihydropyrimidine dehydrogenase in cancer patients.Journal of Clinical Oncology, 1994
- Multifocal inflammatory leukoencephalopathy with 5‐fluorouracil and levamisoleAnnals of Neurology, 1992
- A New Syndrome: Ascites, Hyperbilirubinemia, and Hypoalbuminemia after Biochemical Modulation of Fluorouracil with N-Phosphonacetyl-L-Aspartate (PALA)Annals of Internal Medicine, 1991
- Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndromeCancer, 1991
- Tumor lysis syndrome in nonhematopoietic neoplasmsCancer, 1989
- Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.Journal of Clinical Investigation, 1988
- Fatal acute tumor lysis syndrome with metastatic breast carcinomaCancer, 1987
- Clearance of Continuously Infused 5-Fluorouracil in Adults Having Lung or Gastrointestinal Carcinoma with or without Hepatic MetastasesDrug Intelligence & Clinical Pharmacy, 1982
- The metabolism of uracil‐2‐14C and the granulocyte response to endotoxin as indicators of the toxicity produced in patients receiving 5‐fluorouracilClinical Pharmacology & Therapeutics, 1967